These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22487861)

  • 1. Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C.
    Stein VM; Crooks A; Ding W; Prociuk M; O'Donnell P; Bryan C; Sikora T; Dingemanse J; Vanier MT; Walkley SU; Vite CH
    J Neuropathol Exp Neurol; 2012 May; 71(5):434-48. PubMed ID: 22487861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.
    Patterson MC; Vecchio D; Prady H; Abel L; Wraith JE
    Lancet Neurol; 2007 Sep; 6(9):765-72. PubMed ID: 17689147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of miglustat on evolution of atypical presentation of late-infantile-onset Niemann-Pick disease type C with early cognitive impairment, behavioral dysfunction, epilepsy, ophthalmoplegia, and cerebellar involvement: a case report.
    Cuisset JM; Sukno S; Trauffler A; Latour P; Dobbelaere D; Michaud L; Vallée L
    J Med Case Rep; 2016 Sep; 10(1):241. PubMed ID: 27599728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.
    Boudewyn LC; Sikora J; Kuchar L; Ledvinova J; Grishchuk Y; Wang SL; Dobrenis K; Walkley SU
    Neurobiol Dis; 2017 Sep; 105():257-270. PubMed ID: 28610891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early miglustat therapy in infantile Niemann-Pick disease type C.
    Di Rocco M; Dardis A; Madeo A; Barone R; Fiumara A
    Pediatr Neurol; 2012 Jul; 47(1):40-3. PubMed ID: 22704015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.
    Héron B; Valayannopoulos V; Baruteau J; Chabrol B; Ogier H; Latour P; Dobbelaere D; Eyer D; Labarthe F; Maurey H; Cuisset JM; de Villemeur TB; Sedel F; Vanier MT
    Orphanet J Rare Dis; 2012 Jun; 7():36. PubMed ID: 22676771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete recovery from psychosis upon miglustat treatment in a juvenile Niemann-Pick C patient.
    Szakszon K; Szegedi I; Magyar A; Oláh E; Andrejkovics M; Balla P; Lengyel A; Berényi E; Balogh I
    Eur J Paediatr Neurol; 2014 Jan; 18(1):75-8. PubMed ID: 24119781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of miglustat in Niemann-Pick C disease: a single centre experience.
    Ginocchio VM; D'Amico A; Bertini E; Ceravolo F; Dardis A; Verrigni D; Bembi B; Dionisi-Vici C; Deodato F
    Mol Genet Metab; 2013 Nov; 110(3):329-35. PubMed ID: 23973268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cataplexy in Niemann-Pick disease type C with the use of miglustat.
    Zarowski M; Steinborn B; Gurda B; Dvorakova L; Vlaskova H; Kothare SV
    Eur J Paediatr Neurol; 2011 Jan; 15(1):84-7. PubMed ID: 20207562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.
    Sedel F; Chabrol B; Audoin B; Kaphan E; Tranchant C; Burzykowski T; Tourbah A; Vanier MT; Galanaud D
    J Neurol; 2016 May; 263(5):927-936. PubMed ID: 26984608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
    Pérez-Poyato MS; Gordo MM; Marfa MP
    Gene; 2012 Sep; 506(1):207-10. PubMed ID: 22750297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year.
    Chien YH; Lee NC; Tsai LK; Huang AC; Peng SF; Chen SJ; Hwu WL
    J Inherit Metab Dis; 2007 Oct; 30(5):826. PubMed ID: 17603755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miglustat in Niemann-Pick disease type C patients: a review.
    Pineda M; Walterfang M; Patterson MC
    Orphanet J Rare Dis; 2018 Aug; 13(1):140. PubMed ID: 30111334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miglustat: a review of its use in Niemann-Pick disease type C.
    Lyseng-Williamson KA
    Drugs; 2014 Jan; 74(1):61-74. PubMed ID: 24338084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect.
    Nadjar Y; Hütter-Moncada AL; Latour P; Ayrignac X; Kaphan E; Tranchant C; Cintas P; Degardin A; Goizet C; Laurencin C; Martzolff L; Tilikete C; Anheim M; Audoin B; Deramecourt V; De Gaillarbois TD; Roze E; Lamari F; Vanier MT; Héron B
    Orphanet J Rare Dis; 2018 Oct; 13(1):175. PubMed ID: 30285904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
    Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU
    PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.
    Patterson MC; Garver WS; Giugliani R; Imrie J; Jahnova H; Meaney FJ; Nadjar Y; Vanier MT; Moneuse P; Morand O; Rosenberg D; Schwierin B; Héron B
    J Inherit Metab Dis; 2020 Sep; 43(5):1060-1069. PubMed ID: 32324281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry.
    Patterson MC; Mengel E; Vanier MT; Moneuse P; Rosenberg D; Pineda M
    Orphanet J Rare Dis; 2020 Apr; 15(1):104. PubMed ID: 32334605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine profile and cholesterol levels in patients with Niemann-Pick type C disease presenting neurological symptoms: in vivo effect of miglustat and in vitro effect of N-acetylcysteine and coenzyme Q10.
    Hammerschmidt TG; Donida B; Faverzani JL; Moura AP; Dos Reis BG; Machado AZ; Kessler RG; Sebastião FM; Reinhardt LS; Moura DJ; Vargas CR
    Exp Cell Res; 2022 Jul; 416(2):113175. PubMed ID: 35487270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.